BFM
APLS

Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Boothbay Fund Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,200
Closed -$2.64M – 2041
2025
Q4 		$2.64M Sell
105,200
-32,400
-24% -$760K 0.04% 484
2025
Q3 		$3.11M Buy
+137,600
New +$3.21M 0.05% 446
2024
Q4 		– Sell
-44,000
Closed -$1.27M – 1479
2024
Q3 		$1.27M Buy
+44,000
New +$1.63M 0.03% 681
2024
Q1 		– Sell
-80,400
Closed -$4.81M – 1567
2023
Q4 		$4.81M Buy
80,400
+32,800
+69% +$1.66M 0.12% 210
2023
Q3 		$1.81M Buy
+47,600
New +$2.09M 0.04% 533
2023
Q2 		– Sell
-107,100
Closed -$7.06M – 1790
2023
Q1 		$7.06M Buy
107,100
+37,300
+53% +$2.15M 0.14% 149
2022
Q4 		$3.61M Buy
69,800
+35,000
+101% +$1.86M 0.08% 347
2022
Q3 		$2.38M Buy
34,800
+7,000
+25% +$414K 0.06% 491
2022
Q2 		$1.26M Sell
27,800
-5,600
-17% -$255K 0.03% 722
2022
Q1 		$1.7M Buy
33,400
+11,400
+52% +$503K 0.04% 641
2021
Q4 		$1.04M Sell
22,000
-1,500
-6% -$59.1K 0.02% 727
2021
Q3 		$775K Sell
23,500
-10,600
-31% -$596K 0.02% 883
2021
Q2 		$2.15M Buy
+34,100
New +$1.76M 0.07% 355
2020
Q1 		– Sell
-401
Closed -$1.23M – 840
2019
Q4 		$1.23M Buy
+401
New +$11.1K 0.11% 265

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boothbay Fund Management's APLS Position: Q1 2026 in Review

Boothbay Fund Management increased its Apellis Pharmaceuticals (APLS) stake by 757% in Q1 2026, buying an estimated $3.49M and bringing the position to 183,522 shares worth $7.38M. The position accounts for 0.1% of the portfolio, ranked #208.

Boothbay Fund Management first reported a position in APLS in Q4 2018 and has held it in 14 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Boothbay Fund Management held 183,522 shares of Apellis Pharmaceuticals worth $7.38M as of Q1 2026.
  • Boothbay Fund Management bought 162,107 Apellis Pharmaceuticals shares in Q1 2026, an estimated $3.49M.
  • Apellis Pharmaceuticals made up 0.1% of Boothbay Fund Management's portfolio in Q1 2026, its #208 holding.
  • Boothbay Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.